INDV
Indivior Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Indivior Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Indivior Pharmaceuticals, Inc.
35.35
Expected move
Inputsspot 35.37exp Mar 19ATM strike 35ATM straddle 7.60IV 42%
SentenceIndivior accounted for approximately 73% and 62% of our revenues for 2025 and 2024, respectively, and we believe in the future will continue to account for a substantial part of our revenues.
basisAQST FY2025 revenue $45MINDV FY2025 revenue $1.2B
SentenceLicense & research agreement with Indivior PLC On January 2, 2018, the Group entered into an agreement with Indivior for the discovery, development and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases.
SentenceMaster Development and Supply Agreement effective the August 1, 2023 by and between Curia New Mexico, LLC and Indivior U.K. Limited
INDV 10-Kaccession 0001628280-26-012237
SentenceCopacker Supply Agreement by and between Reckitt Benckiser Healthcare (U.K.) Limited and RB Pharmaceuticals Limited, dated December 23, 2014
INDV 10-Kaccession 0001628280-26-012237
SentenceMaster Packaging and Supply Agreement effective as of October 1, 2023 by and between Sharp Packaging Services, LLC, Indivior Inc., and Indivior U.K. Limited
INDV 10-Kaccession 0001628280-26-012237
Indivior Pharmaceuticals has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
—